Loading ETF profile…
Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| NVO | Novo Nordisk A/S | 12.97% | $7.07M |
| LLY | Eli Lilly & Co | 12.92% | $7.04M |
| PFE | Pfizer Inc | 6.41% | $3.49M |
| KLRA | Kailera Therapeutics Inc | 6.07% | $3.30M |
| VKTX | Viking Therapeutics Inc | 5.89% | $3.21M |
| 1093.HK | CSPC Pharmaceutical Group Ltd | 5.41% | $2.95M |
| 4519.T | Chugai Pharmaceutical Co Ltd | 4.52% | $2.46M |
| 1672.HK | Ascletis Pharma Inc | 4.10% | $2.24M |
| AZN | AstraZeneca PLC | 3.83% | $2.09M |
| AMGN | Amgen Inc | 3.80% | $2.07M |
| ZEAL.CO | Zealand Pharma A/S | 3.78% | $2.06M |
| 128940.KS | Hanmi Pharm Co Ltd | 3.76% | $2.05M |
| ROP.SW | Roche Holding AG | 3.05% | $1.66M |
| GPCR | Structure Therapeutics Inc | 2.92% | $1.59M |
| MBX | MBX Biosciences Inc | 2.71% | $1.48M |
| 3933.HK | United Laboratories International Holdings Ltd/The | 2.64% | $1.44M |
| 3692.HK | Hansoh Pharmaceutical Group Co Ltd | 2.58% | $1.41M |
| 1276.HK | Jiangsu Hengrui Pharmaceuticals Co Ltd | 2.57% | $1.40M |
| 1801.HK | Innovent Biologics Inc | 2.36% | $1.29M |
| GUBRA.CO | Gubra A/S | 1.87% | $1.02M |
| GILD | Gilead Sciences Inc | 1.72% | $938.00K |
| RYTM | Rhythm Pharmaceuticals Inc | 1.61% | $876.58K |
| 4507.T | Shionogi & Co Ltd | 1.24% | $677.40K |
| FGXXX | First American Government Obligations Fund 12/01/2031 | 1.08% | $589.05K |
| WVE | WaVe Life Sciences Ltd | 0.84% | $456.85K |